drugset / Trial / NCT05202379
CC-42344 Safety Study in Healthy Participants
Phase 1
Completed
80 enrolled
Cocrystal Pharma, Inc.
Cocrystal Pharma Australia Pty Ltd. · collabLinear Clinical Research · collab
RandomizedSequentialQuadruple-blindOther
Summary
CC-42344 Phase 1 study with single-ascending dose (SAD) and multiple-ascending dose (MAD) parts.
Timeline
- Start
- 2022-02-11
- Primary completion
- 2023-03-29
- Completion
- 2023-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CC-42344 | Unknown | — | Oral |